AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Malignancy marker for therapy planning

Summary

Blood based test for an early classification of aggressive prostate cancers for personalized therapy planning.

Technology Benefits

Early classification of aggressive prostate cancers for personalized therapy planning.
Applicable for analyzing tissue samples and liquid biopsies.
Also relevant for other tumor entities (e.g. esophagus, breast cancer).
Additional biomarker that can be measured in an easy and objective way.

Technology Application

Prostate cancer diagnosis and classification, Therapeutic strategies

Detailed Technology Description

Vimentin 3 (Vim3) has been discovered as
biomarker, which correlates with the risk of
progression of prostate cancer. Results
show high expression of Vim3 in cells of
metastatic prostate and low expression in
non-metastatic cancer, thus demonstrating
the potential of Vim3 for risk stratification of
localized prostate carcioma to enable personalized therapy planning

Type of Cooperation

Licensing

Application Date

02/10/2018 00:00:00

Application No.

WO2018EP58923 20180406

Classes

- international:
G01N33/50
- cooperative:
G01N33/5091; G01N2800/367

Others

Patent application

ID No.

5158

Country/Region

Germany

For more information, please click Here